Published in Neurology on May 13, 2008
Pediatric multiple sclerosis. Nat Rev Neurol (2009) 1.50
Neurocognitive sequelae in African American and Caucasian children with multiple sclerosis. Neurology (2010) 1.48
Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol (2012) 1.04
Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord (2010) 1.01
Cognitive dysfunction in pediatric multiple sclerosis. Neuropsychiatr Dis Treat (2014) 0.99
Therapies for multiple sclerosis: considerations in the pediatric patient. Nat Rev Neurol (2011) 0.93
International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology (2013) 0.89
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol (2014) 0.85
Pediatric multiple sclerosis. Ann Indian Acad Neurol (2009) 0.84
Psychosocial issue in children and adolescents with multiple sclerosis. Neurol Sci (2010) 0.82
Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials. Mult Scler Int (2014) 0.81
Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis. Neurotherapeutics (2016) 0.81
Cognitive impairment and event-related potentials in paediatric multiple sclerosis: 2-year study. Neurol Sci (2011) 0.79
Management of multiple sclerosis in adolescents - current treatment options and related adherence issues. Adolesc Health Med Ther (2010) 0.77
Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies. Adolesc Health Med Ther (2010) 0.77
Disease-modifying therapy of pediatric multiple sclerosis. Neurotherapeutics (2013) 0.77
Early onset multiple sclerosis has worse prognosis than adult onset multiple sclerosis based on cognition and magnetic resonance imaging. Autoimmune Dis (2012) 0.77
Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. BMC Neurol (2013) 0.76
Diagnosis and Management of Multiple Sclerosis in Children. Iran J Child Neurol (2016) 0.75
Behavioral Symptoms in Pediatric Multiple Sclerosis: Relation to Fatigue and Cognitive Impairment. J Child Neurol (2016) 0.75
Longitudinal evaluation of cognitive functioning in pediatric multiple sclerosis: report from the US Pediatric Multiple Sclerosis Network. Mult Scler (2014) 0.75
Cognitive and psychosocial features of childhood and juvenile MS. Neurology (2009) 0.75
Cognitive rehabilitation in children and adolescents with multiple sclerosis. Neurol Sci (2010) 0.75
The computer-based Symbol Digit Modalities Test: establishing age-expected performance in healthy controls and evaluation of pediatric MS patients. Neurol Sci (2017) 0.75
A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study. Neurol Sci (2017) 0.75
Cognitive impairment in pediatric multiple sclerosis. Neurol Sci (2010) 0.75
Measurement and maintenance of reserve in multiple sclerosis. J Neurol (2016) 0.75
The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell (1999) 8.07
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A (1980) 6.31
Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet (2001) 5.09
TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. Cell (2001) 4.60
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol (2011) 2.90
White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2002) 2.72
The novel receptors that mediate the entry of herpes simplex viruses and animal alphaherpesviruses into cells. Rev Med Virol (2000) 2.71
Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol (2005) 2.67
Infectiousness of Mycobacterium tuberculosis in HIV-1-infected patients with tuberculosis: a prospective study. Lancet (2000) 2.67
A two-site monoclonal antibody ELISA for the quantification of the major Dermatophagoides spp. allergens, Der p I and Der f I. J Immunol Methods (1989) 2.56
Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol (2007) 2.51
Numbers of Giardia in the feces of infected children. Am J Trop Med Hyg (1975) 2.38
Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology (2001) 2.24
The human PRR2 gene, related to the human poliovirus receptor gene (PVR), is the true homolog of the murine MPH gene. Gene (1995) 2.19
Cdc42 is required for PIP(2)-induced actin polymerization and early development but not for cell viability. Curr Biol (2000) 2.19
Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology (2010) 2.14
Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord (2009) 2.13
Nectin4/PRR4, a new afadin-associated member of the nectin family that trans-interacts with nectin1/PRR1 through V domain interaction. J Biol Chem (2001) 2.09
Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain (1981) 2.08
Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology (2011) 2.06
Studies of electroimmunodiffusion: immunochemical quantitation of proteins in dilute solutions. Immunochemistry (1969) 2.05
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology (2004) 2.04
Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology (2010) 2.03
Expansion by folinic acid of the peripheral blood progenitor pool after chemotherapy: its use in autografting in acute leukaemia. Br J Haematol (1990) 2.02
Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 2.00
Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine (1992) 1.97
Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology (2003) 1.94
Bile duct injury after laparoscopic cholecystectomy. The United States experience. Surg Endosc (1998) 1.93
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol (2011) 1.93
The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry (2000) 1.91
Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol (2000) 1.88
The V domain of herpesvirus Ig-like receptor (HIgR) contains a major functional region in herpes simplex virus-1 entry into cells and interacts physically with the viral glycoprotein D. Proc Natl Acad Sci U S A (1998) 1.87
Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology (2010) 1.85
Paraplegia following coeliac plexus block. Pain (1993) 1.85
Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 1.83
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler (2005) 1.81
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol (2011) 1.78
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76
Correlation of multiple sclerosis measures derived from T2-weighted, T1-weighted, magnetization transfer, and diffusion tensor MR imaging. AJNR Am J Neuroradiol (2001) 1.75
Electrocautery as a factor in seroma formation following mastectomy. Am J Surg (1998) 1.75
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Mult Scler (2010) 1.74
Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem (1986) 1.74
Physiological outcomes of aerobic exercise training in hemiparetic stroke patients. Stroke (1995) 1.73
The contribution of voxel-based morphometry in staging patients with mild cognitive impairment. Neurology (2006) 1.72
Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol (1994) 1.72
Thoracoscopic repair of H-type tracheoesophageal fistula in the newborn: a technical case report. J Pediatr Surg (2004) 1.72
The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler (2006) 1.71
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology (2011) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. Neurology (1999) 1.65
Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler (1997) 1.65
A diffusion tensor MRI study of cervical cord damage in benign and secondary progressive multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2009) 1.64
Clinical phenotype associated with terminal 2q37 deletion. Clin Genet (1995) 1.63
Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology (2008) 1.63
1alpha,25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. J Biol Chem (2001) 1.62
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain (2003) 1.60
Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J (1993) 1.59
Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology (2009) 1.59